Evidence map›Paper›PMID 42606694›Full record

ArticleJournal of biochemical and molecular toxicology2026

Fisetin Attenuates Amyloid-Beta-Induced Neurotoxicity in Human Neuroblastoma SH-SY5Y Cells: Integrating In Silico Target Prediction and In Vitro Validation.

Charu Jaiswal, Ishika Singh, Abhishek Kumar Singh

Abstract read
In one paragraph

Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Charu JaiswalDepartment of Biotherapeutics Research, Manipal Academy of Higher Education, Manipal, India.
Ishika SinghDepartment of Biotherapeutics Research, Manipal Academy of Higher Education, Manipal, India.
Abhishek Kumar SinghDepartment of Biotherapeutics Research, Manipal Academy of Higher Education, Manipal, India.ORCID https://orcid.org/0000-0002-3186-9898

Funding

Anusandhan National Research Foundation CRG/2022/006612
6 · The paper itself

Abstract

The accumulation of amyloid beta (Aβ) and tau tangles in the brain leads to Alzheimer's disease (AD). Fisetin, a natural flavonoid, is an antioxidant molecule, and its neuroprotective effects are not clearly understood. Therefore, attempts have been made to evaluate the neuroprotective effects of fisetin using in silico methods and an Aβ1-42-induced neurotoxicity model in human neuroblastoma SH-SY5Y cells. In silico studies demonstrated that fisetin binds strongly and with high stability to different proteins, such as ULK1 (autophagy marker), p21 (senescence/cell cycle marker), and synaptophysin (synaptic marker), which are responsible for maintaining brain health and are implicated in AD. Moreover, Aβ1-42 was also found to bind to these protein targets, indicating that Aβ1-42 and fisetin both target common binding sites. In vitro studies on SH-SY5Y cells further confirmed that fisetin promotes cell survival under the toxic effects of Aβ1-42. It reduced oxidative stress and restored the activities of ion channels, which were impaired by Aβ1-42 treatment. Fisetin increased antioxidant defense and restored the activity of molecules that control brain signals. Overall, fisetin acts on multiple targets to protect neurons by reducing oxidative damage, supporting ion channel activity, and inducing the autophagy process.

Indexed as

Amyloid beta-PeptidesFlavonoidsNeuroblastomaNeuroprotective AgentsPeptide FragmentsCell Line, TumorFlavonolsHumansMolecular Docking SimulationOxidative StressAmyloid beta-Peptidesamyloid beta-protein (1-42)fisetinFlavonoidsFlavonolsNeuroprotective AgentsPeptide Fragmentsamyloid‐betafisetinmolecular dockingmolecular dynamics simulationneuroprotectionneurotoxicity

Identifiers

PMID42606694
PMCPMC13480354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.